Innate Pharma SA
corporate_fare Company Profile
Innate Pharma SA (NASDAQ:IPHA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 13 items for IPHA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-17, rated 8/10. Across its 13 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for IPHA spans 6-K, 20-F.
Recent high-impact activity:
- Innate Pharma H1 2026: €19.6M Loss, Negative Equity, Going Concern Resolved by Sobi Deal and €30M Placement
- Innate Pharma Closes €30M Private Placement at 15% Discount, Diluting Shareholders 18.76%
- Innate Pharma Lands $580M Lacutamab Deal with Sobi, Extends Cash Runway to Q3 2027
- Innate Pharma Lands $75M Upfront in Lacutamab Deal with Sobi
- Innate Pharma wraps up Phase 1 dose-escalation enrollment for IPH4502 ADC; early responses emerge in heavily pre-treated cancers
Financial Snapshot
Short Interest & Short Volume
4.09 days to coverFINRA reported short interest of 76,073 shares in IPHA as of the September 15, 2026 settlement, a 7.2% decrease from the prior period — about 4.1 days to cover at its recent average daily volume. On October 2, 2026, 61.1% of IPHA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for IPHA, detected from its recent SEC filings · based on capital-structure filings through 2026-08-19.
€30M Private Placement Closed · 18.76% Dilution to Existing Shareholders
⚠ A more recent filing has been published for this ticker since this signal was computed; it may not yet be reflected — see the filings below.
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
IPHA files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.